MARKET

VRTX

VRTX

Vertex Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

222.70
+4.62
+2.12%
Opening 11:45 10/19 EDT
OPEN
219.30
PREV CLOSE
218.08
HIGH
225.97
LOW
217.25
VOLUME
1.55M
TURNOVER
--
52 WEEK HIGH
306.08
52 WEEK LOW
174.82
MARKET CAP
58.01B
P/E (TTM)
28.15
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Vertex: Looks Cheap, But I Have A Few Concerns
Vertex has seen a setback in its pipeline, yet remains a very impressive growth story.The company sees strong growth, is very profitable, and "controls" the CF business.The latest setback makes shares look very compelling, although competition is aiming to break into the profitable franchise as well.
Seekingalpha · 19h ago
The Week Ahead In Biotech: Spectrum Pharma FDA Decision, Biogen And Abbott Earnings, Cancer Conference
Biopharma stocks, which started the week on a firm footing, lost momentum mid-way through amid market-wide sell-off triggered by waning stimulus hopes.
Benzinga · 22h ago
Stock Market Rally Pauses Amid Stalled Stimulus; Apple iPhone, Amazon Prime Day In Focus, Fastly, Vertex Plunge
Investor's Business Daily · 2d ago
Lilly to Acquire Private Biotech for Boosting Pain Portfolio
Lilly (LLY) inks a deal to acquire Disarm Therapeutics for an upfront payment of $135 million to strengthen its pain and neurological diseases portfolio.
Zacks · 2d ago
Vertex (VRTX) Drops 20% After Failed Drug Trial
Vertex Pharmaceuticals (VRTX) sold off on heavy volume after discontinuing trials of a promising liver disease treatment.
Investopedia · 2d ago
Excellent Entry Point For Vertex Pharmaceuticals After Giving Away -20%
Discontinuation of the Phase 2 study for VX-814 was announced on October 14th, turning investor sentiment sour almost immediately.Investors have punished Vertex, sending shockwaves through the stock and giving away -20% at the beginning of today's play.This recent plunge may give investors an exciting entry opportunity for a fundamentally exquisite company with a flawless balance sheet.We are looking for a breakaway and new support from the current level of $215, where we feel the stock may make a large run up towards its 52-week high of $300.
Seekingalpha · 3d ago
Stock Market News for Oct 16, 2020
U.S. stock markets closed lower on Thursday as the fresh fiscal stimulus impasse continued.
Zacks · 3d ago
Mid-Afternoon Market Update: Dow Down 25 Points; Organogenesis Holdings Shares Jump
Toward the end of trading Thursday, the Dow traded down 0.09% to 28,488.60 while the NASDAQ fell 0.76% to 11,679.22. The S&P also fell, dropping 0.30% to 3,478.07.
Benzinga · 3d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VRTX. Analyze the recent business situations of Vertex Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 26 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VRTX stock price target is 301.13 with a high estimate of 340.00 and a low estimate of 245.00.
EPS
Institutional Holdings
Institutions: 1.20K
Institutional Holdings: 254.82M
% Owned: 97.83%
Shares Outstanding: 260.47M
TypeInstitutionsShares
Increased
393
13.92M
New
223
29.64K
Decreased
264
17.38M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.64%
Pharmaceuticals & Medical Research
-0.28%
Key Executives
Chairman/Director
Jeffrey Leiden
President/Chief Executive Officer/Director
Reshma Kewalramani
Executive Vice President/Chief Administrative Officer
Charles Milstein
Chief Financial Officer/Executive Vice President
Charles Wagner
Executive Vice President/Chief Administrative Officer
Michael Parini
Executive Vice President/Chief Scientific Officer
David Altshuler
Executive Vice President
Stuart Arbuckle
Executive Vice President
Carmen Bozic
Executive Vice President
Gerald Bruce
Executive Vice President
Amit Sachdev
Senior Vice President
Kimberly White
Senior Vice President/Controller
Paul Silva
Senior Vice President
John Gray
Director
David Greenway
Senior Vice President
Nia Tatsis
Lead Director/Independent Director
Bruce Sachs
Independent Director
Sangeeta Bhatia
Independent Director
Lloyd Carney
Independent Director
lloyd Carney
Independent Director
Alan Garber
Independent Director
Terrence Kearney
Independent Director
Yuchun Lee
Independent Director
Margaret McGlynn
Independent Director
Diana McKenzie
Independent Director
William Young
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About VRTX
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Vertex Pharmaceuticals Incorporated stock information, including NASDAQ:VRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VRTX stock methods without spending real money on the virtual paper trading platform.